Q-omics provides the consensus-scored GOLGA8A profile across patient tissues and cancer cell-line models. GOLGA8A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, GOLGA8A is differentially expressed in 7, with the highest sampling consensus in LIHC. Additionally, GOLGA8A RNA expression shows 17,963 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, LIHC, and UVM as cancer lineages where GOLGA8A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GOLGA8A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GOLGA8A survival associations across molecular data types. GOLGA8A RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GOLGA8A RNA expression–survival associations across cancer types. High GOLGA8A expression shows unfavorable associations in KIRC, KICH, STAD and PRAD, but favorable associations in BLCA and PAAD. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for GOLGA8A RNA expression.
This table summarizes GOLGA8A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for GOLGA8A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GOLGA8A shows lower tumor expression in BRCA and KICH and higher tumor expression in LIHC, KIRC, CHOL and COAD. The LIHC box plot shows higher GOLGA8A RNA expression in tumor versus normal tissue (log2 FC = +0.637, t-test p < 0.001).
This table shows molecular features associated with GOLGA8A in patient tissues and cancer cell lines. In patient samples, GOLGA8A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, GOLGA8A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
